Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system

Objective Elagolix is approved for the treatment of moderate-to-severe pain associated with endometriosis. However, the long-term safety of elagolix in a large sample of real-world patients is unknown.